Table 2.
Further treatment after EGFR‐TKI failure
| Further treatment | Re‐biopsy (n = 242) | Liquid biopsy (n = 90) | No re‐biopsy (n = 82) | Total | P |
|---|---|---|---|---|---|
| 3‐TKIs | 64 (26.4) | 28 (31.1) | 5 (6.1) | 97 (23.4) | 0.014 |
| TKI + chemotherapy/radiotherapy | 24 (9.9) | 10 (11.1) | 10 (12.2) | 44 (10.6) | |
| Other TKIs | 7 (2.9) | 2 (2.4) | 2 (2.4) | 12 (2.9) | |
| Former TKIs | 11 (4.5) | 7 (7.8) | 8 (9.8) | 26 (6.3) | |
| Chemotherapy/radiotherapy | 123 (50.8) | 40 (44.4) | 53 (64.6) | 216 (52.2) | |
| Other | 13 (5.4) | 2 (2.2) | 4 (4.9) | 19 (4.6) |
Other tyrosine kinase inhibitors (TKIs) refers to other first or second‐generation EGFR‐TKIs; Other includes best supportive treatment, traditional Chinese medicine, crizotinib, etc. 3‐TKIs, third‐generation TKIs.